Furthermore, a down-regulation of ALX/FPR2 and BLT1 receptors in peripheral blood CD14pos cells relating to RA disease activity suggests that SPM and their receptors seem to have a role also in the remission phase in RA and could be putative biomarkers of inflammation resolution in this disease [51]. The gene discussed is FPR2; the disease is rheumatoid arthritis.